Sign in: Staff/Students
Researchers at the University of Liverpool have been awarded more than £10 million from Horizon 2020 as part of a consortium studying how genes affect a person’s response to drugs.
Pharmacogenomics is a relatively new field and combines pharmacology (the science of drugs) and genomics (the study of genes and their functions) to develop effective, safe medications and doses that will be tailored to a person’s genetic makeup.
The consortium, entitled U-PGx, aims to make actionable pharmacogenomic data and effective treatment optimisation accessible to every European citizen resulting in tailored healthcare.
Better outcomes for patients
The project will implement pre-emptive genotyping, which is the process of determining differences in the genetic make-up of an individual by examining the DNA sequence of an entire panel of important genetic markers. The team will investigate whether this approach is cost-effective and results in a better outcome for patients.
The University’s Institute of Translational Medicine and The Royal Liverpool and Broadgreen Hospital Trust, founding partners of Liverpool Health Partners (LHP), are the only UK members of the consortium and as such they will be receiving approximately £750,000 as part of the project.
Horizon 2020 is the biggest EU Research and Innovation programme, with nearly €80 billion of funding available over seven years (2014 to 2020) – in addition to the private investment that this money will attract. It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market.
Specific treatment plans
Professor Sir Munir Pirmohamed, who leads the work at Liverpool, is the David Weatherall Chair in Medicine at the University and a Consultant Physician at the Royal Liverpool University Hospital. He is also the Associate Executive Pro- Vice-Chancellor for Clinical Research and Executive Director of LHP.
Professor Pirmohamed holds the only NHS Chair of Pharmacogenetics in the UK, and is Director of the M.R.C. Centre for Drug Safety Sciences, and Director of the Wolfson Centre for Personalised Medicine. He is also an inaugural NIHR Senior Investigator, and Fellow of the Academy of Medical Sciences in the UK.
Professor Pirmohamed, said: “The aim of this study is to ultimately allow for a more accurate diagnosis and specific treatment plans for patients.
“Numerous studies have shown that genetic variation in genes can affect how drugs work on individuals, resulting in both under-dosing and overdosing of affected individuals. This in turn increases the risks of non-response and adverse drug reactions.”
Safer and more effective
Since 2005, the Dutch Pharmacogenetics Working Group has produced guidelines of dose recommendations that account for this genetic diversity, and information on eighty gene-drug combinations is now available. In this project, pre-emptive pharmacogenetic testing and stratified prescribing of drugs, based on these pharmacogenetic guidelines, will be implemented in seven European countries and the clinical benefit and cost-effectiveness of this novel approach will be assessed.
Professor Pirmohamed expects personalised medicine to become an essential and integral part of routine health care. He adds: “We are absolutely convinced that using a patient’s genetic profile, instead of choosing the ‘one size fits all’ approach for prescribing drugs, will usher in safer and more effective drug therapy.”
A short video about pharmacogenics can be found here.
You must be logged in to post a comment.
All recent news
Explore hidden world of microbes in new comic book
Engineers partner in `Smarter Testing’ project for aerospace sector
Event: How can we change our fashion consumption to become more sustainable?
Student stories: Industry placements
First patient dosed in latest stage of AGILE COVID-19 drug trial
Our paper on immune responses to COVID vaccine (mostly Pfizer) in 237 healthcare workers, 124 #SARSCoV2 naïve and 113 previously infected, from the PITCH consortium @pitchstudy is out as a pre-print today.
See if you can spot us in the new @NetflixUK series, The Irregulars! 📽️
Our @VictoriaGallery appears in it, as well as other locations across the city including St George’s Plateau, the Palm House in Sefton Park and Falkner Street in the Georgian Quarter.
Professor Michael Parkinson CBE, author of 1985's Liverpool on the Brink, and Liverpool Beyond the Brink in 2019, analyses the Caller Report, the Gov's Best Value inspection into Liverpool City Council